VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Comparison

Imovax Rabies RabAvert
Vaccine Information Vaccine Information
  • Product Name: Rabies Vaccine
  • Tradename: Imovax
  • Manufacturer: Sanofi Pasteur, SA
  • Vaccine Ontology ID: VO_0000063
  • CDC CVX code: 18
  • Type: Inactivated or "killed" vaccine
  • Status: Licensed
  • Location Licensed: USA (License #1724)
  • Host Species for Licensed Use: Human
  • Antigen: Strain PM-1503-3M obtained from the Wistar Institute, Philadelphia, PA.
  • Preparation: The virus strain PM-1503-3M obtained from the Wistar Institute, Philadelphia, PA, is harvested from infected human diploid cells (MRC-5 strain), concentrated by ultrafiltration and is inactivated by beta-propiolactone. One dose of reconstituted vaccine contains less than 100 mg albumin, less than 150 μg neomycin sulfate and 20 μg of phenol red indicator. The vaccine contains no preservative or stabilizer (FDA: Imovax).
  • Immunization Route: Intramuscular injection (i.m.)
  • Storage: The vaccine should be stored in the refrigerator at 2°C to 8°C (35°F to 46°F). Do not freeze (FDA: Imovax).
  • Approved Age for Licensed Use: all ages
  • Contraindication: For postexposure treatment, there are no known specific contraindications to the use of IMOVAX Vaccine. In cases of pre-exposure immunization, there are no known specific contraindications other than situations such as developing febrile illness etc (FDA: Imovax).
  • Description: Imovax is a sterile, stable, freeze-dried suspension of rabies virus prepared from strain PM-1503-3M obtained from the Wistar Institute, Philadelphia, PA. This vaccine must only be used intramuscularly and as a single dose vial (FDA: Imovax).
  • Product Name: Rabies Vaccine
  • Tradename: RabAvert
  • Manufacturer: Novartis Vaccines and Diagnostics
  • Vaccine Ontology ID: VO_0000094
  • CDC CVX code: 18
  • Type: Live, attenuated vaccine
  • Status: Licensed
  • Location Licensed: USA (License #1754)
  • Host Species for Licensed Use: Human
  • Preparation: The strain Flury LEP was obtained from American Type Culture Collection as the 59th egg passage. The growth medium for propagation of the virus is a synthetic cell culture medium with the addition of human albumin, polygeline (processed bovine gelatin) and antibiotics. The virus is inactivated with beta-propiolactone, and further processed by zonal centrifugation in a sucrose density-gradient. The vaccine is lyophilized after addition of a stabilizer solution, which consists of buffered polygeline and potassium glutamate (Rabavert).
  • Immunization Route: Intramuscular injection (i.m.)
  • Storage: RabAvert should be stored protected from light at 2°C to 8°C (36°F to 46°F) (Rabavert).
  • Approved Age for Licensed Use: All ages
  • Contraindication: There is no contraindication to post-exposure immunization. Persons with a history of anaphylactic, anaphylactoid, or other immediate reactions (e.g. hives, swelling of the mouth and throat, difficulty breathing, hypotension, or shock) subsequent to egg ingestion should not be immunized with this vaccine (Rabavert).
  • Description: A sterile freeze-dried vaccine obtained by growing the fixed-virus strain Flury LEP in primary cultures of chicken fibroblasts.
Host Response Host Response

Human Response

  • Immune Response: Seroconversion was often obtained with only one dose. With two doses one month apart, 100% of the recipients developed specific antibody (FDA: Imovax).
  • Side Effects: Most common side effects reported in clinical studies included: injection site reactions, headache, nausea, abdominal pain, muscle aches and dizziness (FDA: Imovax).

Human Response

  • Immune Response: When administered according to the recommended immunization schedule (days 0, 7, 21), 100% of subjects attained a protective titer (Rabavert).
  • Side Effects: The most common side effects reported are: injection site reactions (redness, itching, and swelling), fever, and swollen lymph nodes (Rabavert).
References References
FDA: Imovax: FDA: Imovax vaccine information [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm180097.htm]
Rabavert: Rabavert Package Insert [http://www.novartisvaccines.com/downloads/diseases-products/us-pl-rabavert.pdf]